152 related articles for article (PubMed ID: 37634217)
21. Effects of hormone receptor status on the durable response of trastuzumab-based therapy in metastatic breast cancer.
Park HS; Sohn J; Kim SI; Park S; Park HS; Gho SG; Chung HC; Paik S; Kim GM
Breast Cancer Res Treat; 2017 Jun; 163(2):255-262. PubMed ID: 28243895
[TBL] [Abstract][Full Text] [Related]
22. Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort.
Darlix A; Louvel G; Fraisse J; Jacot W; Brain E; Debled M; Mouret-Reynier MA; Goncalves A; Dalenc F; Delaloge S; Campone M; Augereau P; Ferrero JM; Levy C; Fumet JD; Lecouillard I; Cottu P; Petit T; Uwer L; Jouannaud C; Leheurteur M; Dieras V; Robain M; Chevrot M; Pasquier D; Bachelot T
Br J Cancer; 2019 Dec; 121(12):991-1000. PubMed ID: 31719684
[TBL] [Abstract][Full Text] [Related]
23. Characteristics of patients with brain metastases from human epidermal growth factor receptor 2-positive breast cancer: subanalysis of Brain Metastases in Breast Cancer Registry.
Laakmann E; Witzel I; Neunhöffer T; Park-Simon TW; Weide R; Riecke K; Polasik A; Schmidt M; Puppe J; Mundhenke C; Lübbe K; Hesse T; Thill M; Zahm DM; Denkert C; Fehm T; Nekljudova V; Rey J; Loibl S; Müller V
ESMO Open; 2022 Jun; 7(3):100495. PubMed ID: 35653983
[TBL] [Abstract][Full Text] [Related]
24. Early and Locally Advanced Metaplastic Breast Cancer: Presentation and Survival by Receptor Status in Surveillance, Epidemiology, and End Results (SEER) 2010-2014.
Schroeder MC; Rastogi P; Geyer CE; Miller LD; Thomas A
Oncologist; 2018 Apr; 23(4):481-488. PubMed ID: 29330212
[TBL] [Abstract][Full Text] [Related]
25. Features Associated With Long-Term Survival in Patients With Metastatic Breast Cancer.
Klar N; Rosenzweig M; Diergaarde B; Brufsky A
Clin Breast Cancer; 2019 Aug; 19(4):304-310. PubMed ID: 30827763
[TBL] [Abstract][Full Text] [Related]
26. Characteristics and survival of de novo and recurrent metastatic breast cancer in New Zealand.
Lao C; Kuper-Hommel M; Elwood M; Campbell I; Edwards M; Lawrenson R
Breast Cancer; 2021 Mar; 28(2):387-397. PubMed ID: 33044617
[TBL] [Abstract][Full Text] [Related]
27. Breast cancer subtypes and survival in patients with brain metastases.
Nam BH; Kim SY; Han HS; Kwon Y; Lee KS; Kim TH; Ro J
Breast Cancer Res; 2008; 10(1):R20. PubMed ID: 18307763
[TBL] [Abstract][Full Text] [Related]
28. Characteristics of Patients With Metastatic Breast Cancer Who Survived more than 10 Years.
Kikuchi M; Fujii T; Honda C; Tanabe K; Nakazawa Y; Ogino M; Obayashi S; Shirabe K
Anticancer Res; 2023 Jan; 43(1):217-221. PubMed ID: 36585173
[TBL] [Abstract][Full Text] [Related]
29. Ixabepilone and Carboplatin for Hormone Receptor Positive/HER2-neu Negative and Triple Negative Metastatic Breast Cancer.
Osborne C; Challagalla JD; Eisenbeis CF; Holmes FA; Neubauer MA; Koutrelakos NW; Taboada CA; Vukelja SJ; Wilks ST; Allison MA; Reddy P; Sedlacek S; Wang Y; Asmar L; O'Shaughnessy J
Clin Breast Cancer; 2018 Feb; 18(1):e89-e95. PubMed ID: 28779904
[TBL] [Abstract][Full Text] [Related]
30. Brain Metastases in the Setting of Stable Versus Progressing Extracranial Disease Among Patients With Metastatic Breast Cancer.
Kojundzic I; Chehade R; Gonzalez CAC; Fritz J; Moravan V; Sahgal A; Warner E; Das S; Jerzak KJ
Clin Breast Cancer; 2024 Feb; 24(2):156-161. PubMed ID: 38135543
[TBL] [Abstract][Full Text] [Related]
31. First-line treatment patterns and clinical outcomes in patients with HER2-positive and hormone receptor-positive metastatic breast cancer from registHER.
Tripathy D; Kaufman PA; Brufsky AM; Mayer M; Yood MU; Yoo B; Quah C; Yardley D; Rugo HS
Oncologist; 2013; 18(5):501-10. PubMed ID: 23652380
[TBL] [Abstract][Full Text] [Related]
32. Treatment and outcomes in patients with central nervous system metastases from breast cancer in the real-life ESME MBC cohort.
Pasquier D; Darlix A; Louvel G; Fraisse J; Jacot W; Brain E; Petit A; Mouret-Reynier MA; Goncalves A; Dalenc F; Deluche E; Fresnel JS; Augereau P; Ferrero JM; Geffrelot J; Fumet JD; Lecouillard I; Cottu P; Petit T; Uwer L; Jouannaud C; Leheurteur M; Dieras V; Robain M; Mouttet-Audouard R; Bachelot T; Courtinard C
Eur J Cancer; 2020 Jan; 125():22-30. PubMed ID: 31835235
[TBL] [Abstract][Full Text] [Related]
33. A Phase II Single-arm Study of Palbociclib in Patients With HER2-positive Breast Cancer With Brain Metastases and Analysis of ctDNA in Patients With Active Brain Metastases.
Shah AN; Santa-Maria CA; Mukhija D; Shah N; Kang AK; Kumthekar P; Burdett K; Chandra S; Chang J; Tsarwhas D; Woodman J; Jovanovic B; Gerratana L; Gradishar W; Cristofanilli M
Clin Breast Cancer; 2023 Apr; 23(3):324-329. PubMed ID: 36621430
[TBL] [Abstract][Full Text] [Related]
34. Clinicopathological and Treatment-Associated Prognostic Factors in Patients with Breast Cancer Leptomeningeal Metastases in Relation to Tumor Biology.
Griguolo G; Pouderoux S; Dieci MV; Jacot W; Bourgier C; Miglietta F; Firmin N; Conte P; Viala M; Guarneri V; Darlix A
Oncologist; 2018 Nov; 23(11):1289-1299. PubMed ID: 30120164
[TBL] [Abstract][Full Text] [Related]
35. Treatment patterns and clinical outcomes for patients with de novo versus recurrent HER2-positive metastatic breast cancer.
Yardley DA; Kaufman PA; Brufsky A; Yood MU; Rugo H; Mayer M; Quah C; Yoo B; Tripathy D
Breast Cancer Res Treat; 2014 Jun; 145(3):725-34. PubMed ID: 24706168
[TBL] [Abstract][Full Text] [Related]
36. Treatment and outcomes of patients in the Brain Metastases in Breast Cancer Network Registry.
Witzel I; Laakmann E; Weide R; Neunhöffer T; Park-Simon TJ; Schmidt M; Fasching PA; Hesse T; Polasik A; Mohrmann S; Würschmidt F; Schem C; Bechtner C; Würstlein R; Fehm T; Möbus V; Burchardi N; Loibl S; Müller V
Eur J Cancer; 2018 Oct; 102():1-9. PubMed ID: 30099223
[TBL] [Abstract][Full Text] [Related]
37. A Phase Ib Trial of Durvalumab in Combination with Trastuzumab in HER2-Positive Metastatic Breast Cancer (CCTG IND.229).
Chia S; Bedard PL; Hilton J; Amir E; Gelmon K; Goodwin R; Villa D; Cabanero M; Tu D; Tsao M; Seymour L
Oncologist; 2019 Nov; 24(11):1439-1445. PubMed ID: 31420468
[TBL] [Abstract][Full Text] [Related]
38. Landscape of HER2-low metastatic breast cancer (MBC): results from the Austrian AGMT_MBC-Registry.
Gampenrieder SP; Rinnerthaler G; Tinchon C; Petzer A; Balic M; Heibl S; Schmitt C; Zabernigg AF; Egle D; Sandholzer M; Singer CF; Roitner F; Hager C; Andel J; Hubalek M; Knauer M; Greil R
Breast Cancer Res; 2021 Dec; 23(1):112. PubMed ID: 34906198
[TBL] [Abstract][Full Text] [Related]
39. Hormone Receptor-Positive Breast Cancer Has a Worse Prognosis in Male Than in Female Patients.
Li X; Yang J; Krishnamurti U; Huo L; Ward KC; O'Regan R; Peng L
Clin Breast Cancer; 2017 Aug; 17(5):356-366. PubMed ID: 28576631
[TBL] [Abstract][Full Text] [Related]
40. Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases: Updated Exploratory Analysis of the HER2CLIMB Randomized Clinical Trial.
Lin NU; Murthy RK; Abramson V; Anders C; Bachelot T; Bedard PL; Borges V; Cameron D; Carey LA; Chien AJ; Curigliano G; DiGiovanna MP; Gelmon K; Hortobagyi G; Hurvitz SA; Krop I; Loi S; Loibl S; Mueller V; Oliveira M; Paplomata E; Pegram M; Slamon D; Zelnak A; Ramos J; Feng W; Winer E
JAMA Oncol; 2023 Feb; 9(2):197-205. PubMed ID: 36454580
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
